Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
Boehringer Ingelheim has entered into a transformative €1.18 billion agreement to acquire NBE-Therapeutics, a clinical-stage biotech company based in Switzerland. This strategic acquisition is set ... Read More
Merck acquisition of OncoImmune: A strategic move to strengthen COVID-19 treatment pipeline
In a significant acquisition aimed at enhancing its COVID-19 therapeutic offerings, pharmaceutical giant Merck has entered into an all-cash deal valued at $425 million to ... Read More
Bristol Myers Squibb completes $13.1bn acquisition of MyoKardia: A strategic move to strengthen cardiovascular portfolio
Bristol Myers Squibb has successfully completed its acquisition of MyoKardia, a clinical-stage biopharmaceutical company based in California. The $13.1 billion deal, announced in October 2020, ... Read More
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the acquisition of VelosBio, a clinical-stage biopharmaceutical company ... Read More
Novo Nordisk’s $1.8bn acquisition of Emisphere Technologies: What it means for the future of oral biologics
Danish pharmaceutical giant Novo Nordisk has reached a significant milestone in the development of oral biologic therapies, agreeing to acquire US-based drug delivery innovator Emisphere ... Read More
FTC grants conditional approval for Mylan’s acquisition of Upjohn: What this means for the pharma industry
The U.S. Federal Trade Commission (FTC) has granted conditional approval for Mylan’s acquisition of Upjohn, Pfizer’s off-patent branded and generic medicines business. This strategic merger ... Read More
Novartis acquires Vedere Bio to advance optogenetic gene therapy for vision restoration
In a significant acquisition that could reshape the landscape of gene therapy for vision restoration, Swiss pharmaceutical giant Novartis has acquired Vedere Bio, a US-based ... Read More
Bayer to acquire Asklepios BioPharmaceutical in $4bn deal: A strategic move in gene therapy innovation
In a significant development within the pharmaceutical industry, German pharma giant Bayer has reached an agreement to acquire the US-based clinical-stage gene therapy company Asklepios ... Read More
Gilead Sciences completes $21bn acquisition of Immunomedics: A new era in cancer treatment
Gilead Sciences, a leading US-based pharmaceutical giant, has successfully concluded its $21 billion acquisition of Immunomedics, a New Jersey-based biopharmaceutical company renowned for its advancements ... Read More
Endo International to acquire BioSpecifics Technologies in $658m deal
In a strategic move to strengthen its portfolio, Endo International has reached an agreement to acquire BioSpecifics Technologies, a commercial-stage biopharmaceutical company based in New ... Read More